A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
about
New developments in the management of moderate-to-severe hemophilia BPrevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)Treatment of hemophilia B: focus on recombinant factor IX.Scratching the surface of allergic transfusion reactions.A survey of the management of newborns with severe hemophilia in Canada.Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.Haemophilia B: current pharmacotherapy and future directions.Emerging drugs for hemophilia B.Current management of hemophilia B: recommendations, complications and emerging issues.Research in haemophilia B--approaching the request for high evidence levels in a rare disease.A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Implementation of a recombinant factor IX Fc fusion protein extended-infusion desensitization protocol.A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.Guidelines for the management of hemophilia.
P2860
Q26751323-89D1DD09-1377-4B5C-AC01-AD6E2D223792Q30655343-55FA7FAD-7FC8-406F-BBD0-079CE280BC2CQ34200694-6A206F59-DDD0-4DC0-911D-E7AF398E8122Q34329068-788A5892-0905-464C-A477-4081C9C0C83FQ37012102-6CB2B35F-309D-4A95-9E09-80B85BB8915EQ37248441-EBDB47AF-5F6F-4C6B-8BB0-BC20DF96D7F1Q37342834-95429DE9-798C-46DF-97FD-7AC001A9D3CEQ38040458-DF62C4F7-9ACB-478B-B7E8-D66FE0938EF1Q38237476-0E930DBF-731E-4B22-8389-D59E90C9641BQ38238972-52AACA8A-C9F6-4CB8-A3AB-E4CC6937E3F0Q38286306-FAEA389E-43BC-4F73-ACC9-87553952B407Q42623251-5E5EF33C-C77C-4B3F-95EF-FAB1E311CE25Q45838031-5AFBF4E3-C712-4B71-8A04-5F207CE1777AQ45865769-04E6803F-4CFA-4531-A408-2323B5917DDAQ45866041-83A75783-ECFE-46D6-B664-8BBCB0FF9A29Q45868626-925A44F5-79B8-4D3A-A318-47D3AF5DF4ABQ45875465-31B1E620-15BA-4F04-B558-31E1E312592BQ45880345-91F5DD05-AA90-4BAD-8517-8458FFCD15FA
P2860
A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A retrospective study to descr ...... n subjects with haemophilia B.
@en
A retrospective study to descr ...... n subjects with haemophilia B.
@nl
type
label
A retrospective study to descr ...... n subjects with haemophilia B.
@en
A retrospective study to descr ...... n subjects with haemophilia B.
@nl
prefLabel
A retrospective study to descr ...... n subjects with haemophilia B.
@en
A retrospective study to descr ...... n subjects with haemophilia B.
@nl
P2093
P2860
P921
P1433
P1476
A retrospective study to descr ...... n subjects with haemophilia B.
@en
P2093
A Tagliaferri
H Pollmann
W Richey Neuman
P2860
P304
P356
10.1111/J.1365-2516.2011.02436.X
P577
2011-05-01T00:00:00Z